Pharmabiz1h
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
BioPharma Dive17h
Can the Fed’s rate cut change biotech’s ‘new normal’?
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
NJBIZ18h
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...
Strong Buy Rating for Roivant Sciences Backed by Strategic Dermavant Divestiture and Promising Clinical Pipeline
Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Roivant Sciences (ROIV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Progyny (PGNY – Research Report) and Roivant ...